New Peer-Reviewed Publications Highlight Effectiveness of OMNI® Surgical System with TruSync™ Technology in Reducing IOP and Medication Usage in Cataract Combination Procedures, Standalone Procedures, and in African Americans - Sight Sciences ( NASDAQ:SGHT )
MENLO PARK, Calif., Nov. 11, 2025 ( GLOBE NEWSWIRE ) -- Sight Sciences, Inc. ( NASDAQ:SGHT ) ( Sight Sciences, or the Company ) , an eyecare company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, announced ...
Brown Capital Discloses $31 Million Sale of Vericel Stock as Small-Cap Biotech Reports Earnings
On Tuesday, Baltimore-based Brown Capital Management reported selling 861,020 shares of Vericel Corporation for an estimated $30.9 million based on the average share price in the third quarter.According to a filing with the Securities and Exchange Commission released Tuesday, Brown Capital ...
Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off
Baltimore-based Brown Capital Management reported a sale of 376,359 Glaukos Corporation shares for an estimated $34.6 million in the third quarter, according to an SEC filing.Brown Capital Management disclosed in an SEC filing on Tuesday that it reduced its holding in Glaukos Corporation ( ...
Why Glaukos Stock Zoomed Almost 14% Higher on Thursday
The company's recent past featured robust growth, and it anticipates continued rises into the near future.
Glaukos ( GKOS ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Oct. 29, 2025, at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
GKOS Stock Surges Following Q3 Earnings & Revenue Beat, Guidance Raised
Glaukos reported a narrower Q3 loss, strong 38% sales jump, and raised 2025 outlook as iDose TR and Epioxa fuel momentum across key franchises.
Cardinal Health Posts Upbeat Q1 Results, Joins Guardant Health, Glaukos, C.H. Robinson And Other Big Stocks Moving Higher On Thursday - Cardinal Health ( NYSE:CAH ) , Bausch Health Companies ( NYSE:BHC )
U.S. stocks were mixed, with the Dow Jones index gaining around 200 points on Thursday. Shares of Cardinal Health, Inc. ( NYSE:CAH ) rose sharply during Thursday's session after the company reported better-than-expected first-quarter financial results and raised its FY25 adjusted EPS guidance ...
Alphabet To Rally Around 22%? Here Are 10 Top Analyst Forecasts For Thursday - Caterpillar ( NYSE:CAT ) , Chipotle Mexican Grill ( NYSE:CMG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Needham raised Ionis Pharmaceuticals Inc ( NASDAQ:IONS ) price target from $78 to $90.
Why Alphabet Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket - CERo Therapeutics Hldgs ( NASDAQ:CERO ) , Aditxt ( NASDAQ:ADTX )
Shares of Alphabet Inc. ( NASDAQ:GOOGL ) rose sharply in today's pre-market trading as the company reported better-than-expected financial results for the third quarter after the market closed on Wednesday.
Glaukos ( GKOS ) Reports Q3 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of +40.74% and +9.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
IQVIA Holdings ( IQV ) Tops Q3 Earnings and Revenue Estimates
IQVIA (IQV) delivered earnings and revenue surprises of +1.35% and +0.86%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Booking Holdings To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday - Carpenter Technology ( NYSE:CRS ) , Booking Holdings ( NASDAQ:BKNG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Stifel cut DraftKings Inc ( NASDAQ:DKNG ) price target from $51 to $50.
This Five Below Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday - Five Below ( NASDAQ:FIVE ) , Booking Holdings ( NASDAQ:BKNG )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
DexCom ( DXCM ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Glaukos ( GKOS ) Report Negative Earnings Next Week? What You Should Know
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Valitor Appoints Biotech and Ophthalmic Industry Veteran Gregory D. Kunst as Chief Executive Officer
BERKELEY, Calif., Oct. 17, 2025 ( GLOBE NEWSWIRE ) -- Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced the appointment of Gregory D. Kunst as chief executive officer and member of the board of directors.
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
Company expects to fully repay existing financial debts in 2026 NCX 470 NDA submissions in U.S. ( H1 2026 ) and subsequently in China Milestones payable on U.S. NDA submission and on approval Glaukos extends NCX 1728 research agreement
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
Attachment ...
Glaukos Builds Dual Growth Engines Amid Market Headwinds
GKOS raises revenue guidance after record 1H sales, fueled by iDose TR adoption and expanding international glaucoma momentum.
Glaukos ( GKOS ) Q2 Revenue Jumps 30%
Glaukos ( NYSE:GKOS ) , a medical technology company focused on novel ophthalmic therapies, announced its financial results for the second quarter on July 30, 2025. The company reported GAAP revenue of $124.1 million, beating analyst expectations of $115.5 million by 7.4%.
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
Glaukos' second-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Glaukos ( GKOS ) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of +7.69% and +8.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
GKOS posts record Q1 on iDose TR strength, but reimbursement hurdles and legacy declines may hurt its near-term outlook.
What Makes Glaukos ( GKOS ) a New Buy Stock
Glaukos (GKOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can Glaukos ( GKOS ) Climb 34.4% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for Glaukos (GKOS) points to a 34.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors
HAMPTON, N.J., June 06, 2025 ( GLOBE NEWSWIRE ) -- Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) today announced that Denice M. Torres has been elected to the company's Board of Directors.
Here's Why You Should Retain Glaukos Stock in Your Portfolio
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
This Parsons Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Glaukos ( NYSE:GKOS ) , Parsons ( NYSE:PSN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
GKOS Stock Falls Despite Q1 Earnings & Revenue Beat, Margins Decline
Glaukos' first-quarter results showcase a strong uptick in revenues. However, continued operating loss remains a cause of concern.
Glaukos ( GKOS ) Reports Q1 Loss, Tops Revenue Estimates
Glaukos (GKOS) delivered earnings and revenue surprises of 33.33% and 3.84%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ECL Stock Up in Pre-Market Following Q1 Earnings Meet Estimates
Ecolab's robust performance across the majority of its segments drives its first-quarter organic sales despite business challenges.
RVTY Rises as Q1 Earnings & Sales Beat Estimates, '25 Sales View Up
Revvity's first-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.
Avantor Stock Declines Despite Q1 Earnings In-Line, Revenues Down Y/Y
AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.
Here's Why You Should Hold the GEHC Stock in Your Portfolio for Now
GE HealthCare's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
Integer Holdings Q1 Earnings & Revenues Beat Estimates, Margins Expand
ITGR tops first-quarter estimates with strong sales and EPS growth. Margins expand, driven by new products, acquisitions, and operational efficiency.
Here's Why You Should Add Veeva Stock to Your Portfolio Now
VEEV's robust product portfolio and a slew of strategic deals raise optimism about the stock.
WST Stock Rises on Q1 Earnings Beat, EPS View Up on Tariff & FX Benefit
West Pharmaceutical's first-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
Earnings Preview: Mettler-Toledo ( MTD ) Q1 Earnings Expected to Decline
Mettler-Toledo (MTD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ISRG Stock Falls Despite Q1 Earnings Beat, Gross Margin Contracts
ISRG's first-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
Glaukos ( GKOS ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strength Seen in Veracyte ( VCYT ) : Can Its 13.0% Jump Turn into More Strength?
Veracyte (VCYT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals
Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space
ALC, GKOS and REGN are well-positioned to benefit from the evolving space of cell-based ophthalmic therapy.
Here's How Much You Would Have Made Owning Glaukos Stock In The Last 5 Years - Glaukos ( NYSE:GKOS )
Glaukos GKOS has outperformed the market over the past 5 years by 10.4% on an annualized basis producing an average annual return of 27.01%. Currently, Glaukos has a market capitalization of $5.83 billion.
Here's Why You Should Retain Glaukos Stock in Your Portfolio
GKOS continues to benefit from robust product demand and expansion in new markets. A strong development pipeline raises optimism.
GKOS Crashes Almost 25% After Q4 Earnings: How to Play the Stock?
Glaukos reported robust fourth-quarter revenues, but shares plunged 24.8% post-earnings. Can expanding iDose TR adoption and global growth offset competitive pressures and valuation concerns in 2025?
Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today - Glaukos ( NYSE:GKOS )
Glaukos GKOS has outperformed the market over the past 5 years by 8.36% on an annualized basis producing an average annual return of 23.52%. Currently, Glaukos has a market capitalization of $6.95 billion.
FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery - Glaukos ( NYSE:GKOS )
FDA set an Oct. 20, 2025, review deadline for Glaukos' Epioxa NDA, a next-gen corneal cross-linking therapy for keratoconus. Epioxa met primary efficacy goals with favorable safety, supporting its potential for non-invasive keratoconus treatment.
Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition - Glaukos ( NYSE:GKOS )
Glaukos posted Q4 revenue of $105.5 million, beating estimates of $100.49 million. 2025 revenue guidance set at $475 million-$485 million, aligning with analyst expectations. Get two weeks of free access to pro-level trading tools, including news alerts, scanners, and real-time market insights.
GKOS Stock Falls Despite Q4 Earnings & Revenue Beat, Margins Decline
Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx remain a cause of concern.
